



Contacts:

NATF
617-525-8326

Lynn Kenney
Eisai Inc.
201-746-2294

The North American Thrombosis Forum (NATF)* Announces the 2010 DVTeamCare™ Hospital Award and Calls for Nominations

Award Recognizes Critical Need for Deep Vein Thrombosis (DVT) Prophylaxis in Hospitals

Boston, MA, [date to be inserted]– The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that nominations are being accepted for the 2010 DVTeamCare Hospital Award. Now in its second year, this award provides national recognition to hospitals that have made a significant commitment to preventing DVT and dedicated the necessary resources to achieve this goal.

NATF and Eisai established the DVTeamCare Hospital Award to showcase hospitals that have successfully developed and implemented primary and secondary DVT prophylaxis programs in oncology, general or orthopedic surgery, or major trauma, to name a few. Surveillance studies have shown that without prophylaxis the absolute risk of DVT ranges from 10% – 40% in medical or general surgical patients to 10% – 80% in critical care patients.¹ This year, NATF and Eisai hope to further raise awareness in the oncology community since venous thromboembolism (VTE) is a leading cause of death in cancer patients.^{2,3}

The award is an extension of NATF's goal of enhancing thrombosis education, prevention, diagnosis, and treatment to improve patient outcomes and Eisai's *human health care (hhc)* mission to give first thought to patients and their families and to increasing the benefits that health care provides.

Twenty-two hospitals submitted nominations in 2009. *The Johns Hopkins Hospital* (Maryland) and the *University of California, San Diego Medical Center* tied as award recipients among hospitals with more than 200 beds. *Washington DC Veterans Affairs Hospital* was the award recipient among hospitals with less than 200 beds.

In addition to being recognized nationally in select trade journals, the winning hospitals' protocols and implementation plans will be made available at www.DVTeamCareAward.com as a resource to help other hospitals enhance their efforts to prevent DVT.

How to Nominate a Hospital

Any hospital staff member may submit a nomination through October 15, 2010. A nomination ballot is available online at www.DVTTeamCareAward.com.

The winning hospitals, which will be announced in January 2011, will be selected from the nominee pool by an independent panel of three judges selected by NATF. All judges are nationally and internationally recognized in the areas of thrombosis, hemostasis, and venous thromboembolism (VTE). The judges will score the submissions based on four criteria developed by NATF: intelligence/design of the protocol; implementation; results; and clarity/preparation of the nomination.

About the North American Thrombosis Forum

NATF is a nonprofit organization that focuses on unmet needs and issues related to thrombosis and cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral arterial occlusive disease, and stroke. The five areas of major focus are: 1) basic translational research, 2) clinical research, especially diagnosis and therapy, 3) prevention and education, 4) public policy, and 5) advocacy. NATF's legacy will be to improve patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy, and to broaden training opportunities for physicians, scientists, and other health professionals. For more information about NATF, please visit www.natfonline.org.

About Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately \$3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based *human health care (hhc)* company that discovers, develops and markets products throughout the world.

*NATF has been engaged to independently develop the criteria for and judge the award, and does not endorse or promote any product or service offered by Eisai Inc. or any award nominee or recipient.

References: 1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008; 133:381-453. 2. Khorana AA, Culakova FE, Kuderere NM, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost.* 2007;5:632-634. 3. Ambrus JL, Ambrus CM, Mink IB, et al. Causes of death in cancer patients. *J Med.*1975.;6:61-64.

[Code #]